logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HER2+ metastatic breast cancer: atezolizumab fails to improve PFS in phase 2 KATE2

Study ended prematurely because of futility, more adverse events with drug.